Telix Pharmaceuticals Ltd (ASX: TLX) shares were dominating headlines yesterday after the biopharmaceutical company's shares crashed almost 12% in a single session.
Investors were exiting their positions in Telix after the company announced a $3.3 billion merger with German company ITM.
Image source: Getty Images
What is the merger?
Telix announced a merger with ITM Isotope Technologies Munich SE, a global leader in therapeutic radioisotopes.
As reported by Laura Stewart yesterday, the deal could create a radiopharmaceutical powerhouse, with a combined estimated 2026 revenue of over US$1.3 billion and a deeper supply chain security for Telix's growing pipeline.
Telix said regarding the deal:
The merger will further strengthen Telix's leadership as a vertically integrated radiopharmaceutical company with the capabilities required to develop, manufacture and deliver innovative treatments to patients globally. The combined organisation will be uniquely positioned as a radiopharmaceutical industry leader, differentiated by a world-class scaled isotope manufacturing business with a validated global distribution network, a market-leading commercial precision medicine platform and the industry's most extensive therapeutic radiopharmaceutical pipeline.
However, investors seemingly were unimpressed by the announcement, as Telix shares fell over 11%.
Telix shares remain up 38% year to date.
What is Bell Potter's view?
Following the announcement, Bell Potter provided updated guidance on Telix shares.
The broker's view on Telix's proposed merger with ITM is broadly positive from a strategic perspective, with the transaction providing Telix with significant exposure to the rapidly growing lutetium-177 (Lu-177) market and creating a vertically integrated radiopharmaceutical company spanning isotope production, drug development, and manufacturing.
However, Bell Potter also recognises the near-term risks, including approximately 24% ownership dilution to existing Telix shareholders, around US$302m of additional net debt, potential FY27 earnings dilution, and regulatory and execution risks associated with ITM-11 following the FDA's recent Complete Response Letter.
Overall, the merger strengthens Telix's long-term strategic position and provides exposure to a potentially much larger radiopharmaceutical market.
However, the benefits are likely to take time to flow through to earnings, explaining the muted initial market reaction.
Once in a lifetime opportunity
Bell Potter retained its buy recommendation following the announcement and has an unchanged price target of $19 on Telix shares.
The broker said they are yet to include the earnings impact from the transaction in their forecast.
Nevertheless, it represents a once in a lifetime opportunity to acquire a dominant share in the supply of Lu-177 that is very difficult to replicate. While earnings may take a year or two to realise, the underlying value is obvious. Maintain Buy rating.
The price target from Bell Potter indicates an upside potential of 20% for Telix shares.
